CD1A and neoplasm: In this way, it was considered possible to activate tolerogenic DCs within the tumor mass through stimulation with an immuno-potent CD1-associated lipid/glycolipid, such as α-GalCer, to convert them into immunogenic DCs with sufficient expression of co-stimulatory molecules.